Form 4: Checkpoint Therapeutics CFO Disposes of Shares in Merger Transaction, Receives Cash and Contingent Value Rights

Checkpoint Therapeutics' Chief Financial Officer, William Garrett Gray, has disposed of over 1.4 million shares of common stock in connection with the company's merger agreement, receiving cash and contingent value rights tied to future European regulatory approval of cosibelimab.

Summary

• William Garrett Gray, Chief Financial Officer of Checkpoint Therapeutics, Inc. (CKPT), disposed of 1,446,322 shares of common stock on May 30, 2025.
• The disposition was made pursuant to an offer connected with the Agreement and Plan of Merger, originally dated March 9, 2025, and amended on April 14, 2025.
• For each share, Mr. Gray received $4.10 in cash, net to the holder.
• Additionally, for each share, Mr. Gray received one contractual contingent value right (CVR).
• Each CVR represents the right to receive a payment ranging from $0.20 to $0.70.
• The CVR payment is contingent upon certain milestone payments related to the regulatory approval for cosibelimab in the European Union.
• The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application for cosibelimab receives a positive validation outcome by the European Medicines Agency.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the CFO received a significant cash payment and holds CVRs that offer potential additional value, indicating a successful exit for shareholders in the merger, albeit with some future contingency.

Positives

• The CFO received a fixed cash payment of $4.10 per share, providing immediate liquidity.
• The inclusion of a Contingent Value Right (CVR) offers potential additional upside of $0.20 to $0.70 per share, tied to a key regulatory milestone for cosibelimab in the EU.

Negatives

• The CFO disposed of all 1,446,322 directly owned shares, indicating a complete divestment of direct equity ownership in the company following the merger.
• The full value of the CVR is not guaranteed and is dependent on the successful regulatory approval of cosibelimab in the European Union within a specific timeframe.

Risks

• The value of the Contingent Value Right (CVR) is subject to the regulatory approval of cosibelimab in the European Union.
• There is a time limit of thirty-six (36) months from the positive validation outcome by the European Medicines Agency for the CVR milestone to be achieved, after which the CVR may expire worthless if the milestone is not met.

Future Outlook

The future outlook for the contingent value rights (CVRs) is directly tied to the successful regulatory approval of cosibelimab in the European Union. The CVRs offer a potential additional payment of $0.20 to $0.70 per share if the milestone is achieved within 36 months of a positive EMA validation.

Management Comments

• The disposition of shares was made in connection with an offer pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025, and as amended on April 14, 2025.

Industry Context

This filing reflects a common outcome in the biotechnology and pharmaceutical sectors when a company undergoes a merger or acquisition. The use of Contingent Value Rights (CVRs) is a prevalent mechanism in biotech M&A to bridge valuation gaps and share future risks/rewards, particularly when a key drug candidate's regulatory approval is pending. It allows the acquiring entity to pay a lower upfront cash amount while providing selling shareholders with potential upside if specific clinical or regulatory milestones are met.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in M&A transactions, especially in the biotech and pharmaceutical industries, is a standard practice. Companies like Bristol-Myers Squibb (acquiring Celgene) and Sanofi (acquiring Synthorx) have utilized CVRs to manage risks associated with pipeline assets and future regulatory approvals.
• The structure of the CVR, tied to a specific regulatory milestone (EU approval for cosibelimab) and with a defined payment range and timeframe, aligns with typical industry CVR agreements designed to incentivize and reward successful drug development and commercialization.

Related Party Transactions

• The disposition of 1,446,322 shares by William Garrett Gray, the Chief Financial Officer, is an insider transaction directly related to the company's merger agreement.

Stakeholder Impact

• Shareholders who held common stock at the time of the merger received $4.10 per share in cash plus one CVR per share, providing immediate value and potential future upside.
• The CVR structure aligns the interests of former shareholders with the future success of cosibelimab's regulatory pathway in the EU.

Next Steps

• Monitoring the progress of cosibelimab's marketing authorization application and its validation outcome by the European Medicines Agency.
• Tracking the achievement of the CVR milestone related to cosibelimab's regulatory approval in the European Union within the 36-month timeframe.

Key Dates

Keywords

Checkpoint Therapeutics, CKPT, Form 4, Insider Transaction, Merger Agreement, Contingent Value Right, CVR, Cosibelimab, Regulatory Approval, European Union, Biotechnology, Pharmaceuticals, Stock Disposition